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BACKGROUND: The aim of this study was to report on changes in the diagnostic assessment, patterns of care and survival over time for
pancreatic cancers.
METHODS: A total of 2986 cases of pancreatic cancer from the Digestive Cancer Registry of Burgundy (France) over a 30-year period
(1976–2005) were considered. Non-conditional logistic regressions were carried out to identify the factors associated with resection
for cure and with the use of chemotherapy. A multivariate relative survival analysis was carried out.
RESULTS: Diagnostic procedures have changed. Ultrasonography and computed tomography progressively have become the major
diagnostic procedures. There was a slight improvement in stage: the proportion of stage I–II was 2.8% in the 1976–1980 period and
8.8% in the 2001–2005 period (Po0.001). There was a similar trend in the proportion of cases resected for cure, the corresponding
percentages being 4.5 and 11.3%, respectively (Po0.001). The 5-year relative survival increased from 2.0 to 4.2% (Po0.001). In the
multivariate relative survival analysis, the period remained a significant prognostic factor. Stage, sex, age and histology were
independent prognostic factors.
CONCLUSION: Over a 30-year period, there were minor changes in the stage at diagnosis, resection for cure and prognosis of
pancreatic cancers, although there were improvements in the diagnostic modalities. Pancreatic cancer still represents a major
challenge in oncology.
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Pancreatic cancer is currently generating particular interest
because of its increasing incidence and its particularly poor
prognosis. Numerous developments have taken place in post-
operative resuscitation and non-surgical treatments. These were
initiated in specialised centres and have progressively spread.
Population-based studies that include all of the cases arising in a
well-defined population are the best way to assess the real
management of these cancers. The objective of this study was to
draw a picture of the trends in pre-therapeutic evaluation, stage at
diagnosis, treatment and survival of pancreatic cancers in a well-
defined French population over the past 30 years.
MATERIALS AND METHODS
The population-based digestive cancer registry of Burgundy
(France) records all digestive tract cancers diagnosed in
the resident population of two administrative areas (1050000
according to the 1999 census). Cancer extension at the time of
diagnosis was classified according to the TNM classification. Three
stages were defined: stage I–II (T1–4 N0 M0), stage III (N1 M0)
and stage IV (M1). Non-resected cancers with no evidence of
visceral metastasis were grouped into stage IV and classified as
advanced cases (n¼1301). Those who underwent resection, but
were not staged, were classified as unknown (n¼9). The life status
was known for 2968 patients (99.0%) in January 2008.
Relative survival was calculated. The excess hazard ratio of
death was estimated using a relative survival model based on the
general linear model. A total of 2986 pancreatic cancers were
considered. Ampullary, intrapancreatic bile duct and duodenal
cancers were excluded.
RESULTS
Diagnostic modalities
Diagnostic procedures varied over time (Table 1, Figure 1). There
was a dramatic decrease in the proportion of cases diagnosed at
the time of laparotomy. The diagnosis was based on surgical
findings in 37.4% of the cases over the 1976–1980 period, and in
3.5% of the cases over the 2001–2005 period. Laparoscopy as a
diagnostic tool was used until 1985: 31.3% of patients between
1976 and 1980, and in 13.9% of cases between 1981 and 1985. The
proportion of patients who had an abdominal ultrasound (US)
examination increased from 6.5% (1976–1980) to 87.3% (1991–
1995), then tended to decrease. Computed tomography (CT) scans
were introduced in 1981. It was carried out in 2.4% of the cases
over the 1981–1985 period and in 79.5% over the 2001–2005
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speriod (Po0.001). Endoscopic ultrasonography emerged in the
early 90s and was carried out in 28.5% of cases during the 2001–
2005 period. The use of MRI, which was available since 1991,
remained infrequent.
Stage at diagnosis and treatment
The proportion of stages I and II increased over the first four study
periods from 2.8 to 10.4% (Po0.001), then levelled out. Most cases
of pancreatic cancers were advanced cases.
The proportion of patients who underwent resection for cure
was stable over the first two study periods, increased between the
third (1986–1990) and the fourth (1991–1995), and then remained
stable (Po0.001) (Table 1). The proportion of these patients
receiving adjuvant chemotherapy increased from 5.0% (1986–
1990) to 40.2% (2001–2005). Overall, 22.7% of the patients aged
o65 years were resected for cure. This decreased to 13.7% of those
aged from 65 to 74 years and to 7.8% of patients aged 475 years
(Po0.001). Operative mortality after surgery for cure decreased
significantly over the study period. It was 28.0% over the 1976–
1985 period, 9.5% over the 1986–1995 period and 5.1% over the
1996–2005 period (Po0.001).
Chemotherapy was carried out after resection for cure in 19.4%
of the cases. This proportion was 41.8% during the last study
period. Chemotherapy was carried out in 30.4% of the cases after
palliative resection and in 16.6% in non-resected cases (Po0.001).
Before 1990, palliative chemotherapy was hardly used (3.5% of
cases). The proportion of patients receiving palliative chemother-
apy increased from 10.4% (1991–1995) to 41.8% in the last study
period (Po0.001). Radiotherapy was also used as a palliative
treatment. It emerged after the first period and remained rarely
used ever since.
Survival
Overall 1- and 5-year relative survival rates were, respectively, 19.8
and 4.1%. Survival was higher in females than in males (Po0.001),
in patients under 65 years than in older patients (Po0.001) and
in endocrine tumours compared with the other histological types
(Po0.001) (Table 2). The 5-year relative survival increased from
2.0 to 4.2% between the first and the last time periods (Po0.001).
Stage was the most important determinant of survival. The 5-year
relative survival rate was 25.7% after resection for cure and 2.0%
for the other treatment modalities (Po0.001).
In the multivariate relative survival analysis, sex, age, histolo-
gical type, stage and period of diagnosis were significant
prognostic factors.
DISCUSSION
The data presented here report the management and survival of
pancreatic cancers at a population level over 30 years.
Table 1 Trends in diagnostic procedures, stage and management of pancreatic cancers (%)
1976–1980
(N¼246)
1981–1985
(N¼330)
1986–1990
(N¼479)
1991–1995
(N¼528)
1996–2000
(N¼665)
2001–2005
(N¼738)
Procedures used for diagnosis
Surgical findings 37.4 40.6 26.7 5.5 3.5 3.5
Cholangiography
a 10.0 5.1 10.4 8.8 6.7 3.2
Ultrasonography 6.5 26.7 39.0 87.3 83.9 65.6
Computed
tomography
0.0 2.4 27.1 54.6 74.6 79.7
Magnetic resonance
imaging
— — — 1.1 10.5 9.1
Endoscopic
ultrasonography
— — — 8.9 11.1 28.5
Stage at diagnosis
b
I/II 2.8 4.6 7.8 10.4 8.0 8.8
III 2.0 1.2 2.5 4.8 6.3 5.7
Advanced
c 95.2 94.2 89.7 84.8 85.7 85.5
Treatment
Resection for cure 4.5 4.5 8.7 12.5 11.0 11.3
Palliative surgery 57.2 65.9 55.7 48.5 53.3 48.8
Palliative
chemotherapy
1.7 3.5 4.4 10.4 28.5 41.8
Palliative radiotherapy 0.0 7.7 4.2 4.8 12.5 8.8
Best supportive care
d 37.4 25.7 34.0 37.4 33.2 38.7
aRetrograde or trans-hepatic diagnostic cholangiography.
bUnknown: nine cases.
cMetastatic and/or non-resected cases.
dIncluding medical biliary stent.
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Figure 1 Evolution of imaging in diagnosis strategy
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sOne point of interest of this study was to describe changes in the
diagnostic assessment of pancreatic cancer. No comparable data are
available in the literature. Until the early 1980s, exploration of the
pancreas was difficult, which explains why diagnosis was often based
on operative findings. This was the case in nearly 40% of cancers over
the 1976–1985 period in our study. Diagnosis became easier with the
development of abdominal US examination and then of CT. Both of
these investigations were often carried out, in particular over the 1996–
2000 period. In the most recent period, there was a trend to carry out
CT directly. MRI imaging is still rarely used, whereas the importance of
endoscopic ultrasonography is increasing. Thus, it is clear that the
development of medical imaging has made diagnosis easier.
Changes in diagnostic strategies were not associated with a major
improvement in the stage at diagnosis. The lateness of symptoms
can explain why only limited improvements in the management
of pancreatic cancer can be expected from the development of
diagnostic strategies. The proportion of patients resected for cure
increased from 4.5 to 11.3% and the proportion of those in stage
I–II increased from 2.8 to 8.8%. The fact that improvements were
seen in the first three 5-year periods, before levelling off during the
three following periods, is disappointing. Resection rates for cure
and stage were lower than those reported in hospital-based series
(Bilimoria et al., 2007). Hospital data were provided by specialised
units and as such cannot be used as a reference.
New approaches to the treatment of pancreatic cancer need to be
found. The benefits of adjuvant treatment using chemotherapy
and/or radiotherapy have been reported (Stocken et al., 2005).
However, the benefits on survival, although significant, are
modest. Palliative chemotherapy regimens also improve survival
(Sultana et al., 2008). One of the most striking trends in
the management of pancreatic cancer lies in the reduction of
operative mortality, in particular after surgery for cure. It was 5%
over the last 10-year period, close to figures reported by specialised
teams. Major advances have been made by the way of the thorough
evaluation of associated medical conditions and by improvements
in post-operative resuscitation.
The prognosis of pancreatic cancer remained markedly grim,
with o5% of survivors 5 years after diagnosis. The survival rates
reported here are comparable with those of the US Surveillance
Epidemiology and End Results database (Ries et al.), the
EUROCARE database (Sant et al., 2003), and with the England
and Wales national registry (Mitry et al., 2008). Stage was the major
determinant of survival. Our data also showed a worse prognosis in
men than in women. This had already been reported (Eloubeidi
et al., 2006). At the same age, women probably have lesser co-
morbidity than men. The much better prognosis of endocrine
tumours has already been reported (Fesinmeyer et al., 2005). The
development of these tumours is thought to be slow (Lepage et al.,
2004). In this situation, aggressive treatments are justified.
As symptoms of pancreatic cancer appear late, it is necessary to
make advances in a better understanding of the genetic and
environmental causes, and of the mechanisms involved in its
development. Smoking is the most consistently identified risk
factor, although its role is not as important as for other cancers.
The risk of pancreatic cancer seems to be greater in people having
high-energy diets and lower in those having diets that are rich in
fruits and vegetables. Detection of asymptomatic pancreatic
cancers remains a challenge, as high-risk groups for pancreatic
cancer are not sufficiently known. The association between
diabetes and pancreatic cancer has long been recognised. However,
the prevalence of pancreatic cancer is low. A reliable serological
biomarker with a high likelihood of underlying asymptomatic
pancreatic cancer is needed to yield a successful screening strategy.
In addition, improvements in treatment are still needed.
Table 2 Prognostic factors for pancreatic cancers: univariate and multivariate relative survival analysis
Univariate analysis Multivariate analysis
N 1 year 5 years Hazard ratio 95% CI P-value
Global 2968 19.8% 4.1%
Sex
Males 1652 18.3% 3.4% 1
Females 1316 21.7% 5.1% 0.82 (0.76–0.89) o0.001
Age at diagnosis (years)
o65 809 29.4% 7.6% 1
65–74 922 19.8% 3.5% 1.22 (1.10–1.35) o0.001
75–84 901 15.5% 2.7% 1.33 (1.20–1.48) o0.001
X85 336 7.5% 0.0% 1.98 (1.71–2.30) o0.001
Period of diagnosis
1976–1980 246 9.5% 2.0% 1
1981–1985 324 15.8% 4.5% 0.67 (0.56–0.79) o0.001
1986–1990 471 18.6% 3.7% 0.68 (0.58–0.80) o0.001
1991–1995 527 16.8% 4.7% 0.79 (0.67–0.92) 0.003
1996–2000 664 22.5% 4.4% 0.62 (0.53–0.72) o0.001
2001–2005 736 25.6% 4.2% 0.61 (0.52–0.71) o0.001
Stage
a
I-II 231 59.2 % 24.7 % 1
III 129 50.0% 12.7 % 1.44 (1.12–1.84)
Advanced
b 2599 14.9 % 2.0 % 3.04 (2.56–3.60) o0.001
Morphology
c
No histology 1382 14.2% 1.8% 1
Adenocarcinoma 1375 23.1% 3.7% 0.24 (0.16–0.34) o0.001
Malignant endocrine tumour 82 64.4% 47.1% 1.08 (0.88–1.34) o0.463
Others
c 129 16.8% 6.7% 0.97 (0.89–1.07) 0.550
aMetastatic and/or non-resected cases.
bUnknown: nine cases.
cEpidermoid cancer: 8 cases, lymphoma: 10 cases, undifferentiated carcinoma: 70 cases, sarcoma: 5 cases,
cystadenocarcinoma: 36 cases.
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